Crestline Management, L.P. / DNLI
Crestline Management, L.P.’s Denali Therapeutics Inc Position
Does Crestline Management, L.P. own Denali Therapeutics Inc (DNLI)? Yes — 2.21M shares worth $42M (+91.74% of its 13F portfolio) as of Q1 2026, down from 2.81M shares the prior filed quarter.
Position Value
$42M
Q1 2026
Shares
2.21M
% of Portfolio
+91.74%
Quarters Held
29
currently held
Position History DNLI
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 2.21M | $42M | +91.74% |
| Q4 2025 | 2.81M | $46M | +87.02% |
| Q3 2025 | 3.41M | $50M | +85.26% |
| Q2 2025 | 3.86M | $54M | +86.33% |
| Q1 2025 | 4.16M | $57M | +89.45% |
| Q4 2024 | 4.31M | $88M | +2.92% |
| Q3 2024 | 4.46M | $130M | +6.75% |
| Q2 2024 | 4.76M | $111M | +8.60% |
| Q1 2024 | 5.21M | $107M | +9.45% |
| Q4 2023 | 5.66M | $121M | +10.35% |
| Q3 2023 | 5.96M | $123M | +14.32% |
| Q2 2023 | 6.11M | $180M | +18.83% |
| Q1 2023 | 6.41M | $148M | +17.54% |
| Q4 2022 | 6.86M | $191M | +27.96% |
| Q3 2022 | 7.16M | $220M | +29.71% |
| Q2 2022 | 7.46M | $220M | +28.65% |
| Q1 2022 | 7.46M | $240M | +28.78% |
| Q4 2021 | 7.71M | $344M | +25.68% |
| Q3 2021 | 7.71M | $389M | +36.56% |
| Q2 2021 | 8.14M | $638M | +55.02% |
| Q1 2021 | 9.98M | $570M | +72.40% |
| Q4 2020 | 19.46M | $339M | +35.95% |
| Q3 2020 | 12.20M | $437M | +64.45% |
| Q2 2020 | 13.64M | $330M | +60.47% |
| Q1 2020 | 15.57M | $273M | +78.45% |
| Q4 2019 | 19.46M | $339M | +43.90% |
| Q3 2019 | 19.46M | $298M | +48.02% |
| Q2 2019 | 19.46M | $404M | +54.41% |
| Q1 2019 | 19.46M | $452M | +98.01% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Crestline Management, L.P.’s full portfolio or all institutional holders of DNLI.